Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Trial Details

NCT ID
NCT03936153
Phase
PHASE2
Sponsor
Xynomic Pharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • abexinostat
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Chengdu, China|30.66667,104.06667
  • Dalian, China|38.91222,121.60222

Key Eligibility Criteria

  • Histologically confirmed diffuse large B-cell lymphoma (DLBCL);
  • Have received only two prior standard therapy lines for diffuse large B-cell lymphoma (DLBCL) including anti- cluster of differentiation antigen (a…
  • Confirmed to be unresponsive to the last line of therapy, or have disease progression following the last line of therapy;
  • Have at least one radiologically measurable lymph node or extranodal lymphoid malignant lesion;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →